Status:
COMPLETED
Effect of Anti-CD303 Antibodies in Autoimmune Diseases
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Laboratoire français de Fractionnement et de Biotechnologies
Conditions:
Immune Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature. Since plasmacytoid dendritic cells (pDCs) are the...
Eligibility Criteria
Inclusion
- Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures
- Patient followed in the department of internal medicine of CHU Lille
- Patient with one of the following autoimmune disease, defined according to international criteria: systemic lupus erythematosus, systemic sclerosis, Gougerot-Sjögren syndrome and idiopathic thrombocytopenic purpura
- Being socially insured
Exclusion
- Overlapping syndrome with another autoimmune disease
- Age ≤18 years
- Pregnant or nursing women
- People in emergencies
- Person incapable of consent
- Persons deprived of liberty
- Persons without social security cover
Key Trial Info
Start Date :
December 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2019
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT03370627
Start Date
December 20 2017
End Date
May 25 2019
Last Update
August 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Claude Huriez, CHU
Lille, France